TrialCancer science2020

Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.

Kazutaka Sunami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.